Commercially available fluid biomarkers relevant to HSP can be grouped into three mechanistic categories: axonal injury (e.g., NfL, tau), neuronal cell body damage (e.g., BD-tau, UCHL1), and glial/inflammatory activity (e.g., GFAP, sTREM2, cytokines). This evidence concerns the gene UCHL1 and hereditary spastic paraplegia.